{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:49:53Z","timestamp":1771919393543,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41391-019-0150-5","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T17:39:32Z","timestamp":1555349972000},"page":"600-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy"],"prefix":"10.1038","volume":"22","author":[{"given":"Rishi","family":"Deka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Panizzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Hauger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinit","family":"Nalawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-9552","authenticated-orcid":false,"given":"Brent S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448\u201356.","journal-title":"J Clin Oncol"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation therapy for prostate cancer. New Engl J Med. 2005;352:154\u201364.","journal-title":"New Engl J Med"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","volume":"33","author":"BD Gonzalez","year":"2016","unstructured":"Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2016;33:2021\u20137.","journal-title":"J Clin Oncol"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452\u20138.","journal-title":"J Clin Oncol"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","volume":"60","author":"L Azoulay","year":"2011","unstructured":"Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244\u201350.","journal-title":"Eur Urol"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Hemelrijck Van","year":"2010","unstructured":"Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28:3448\u201356.","journal-title":"J Clin Oncol"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","volume":"65","author":"CG Jespersen","year":"2014","unstructured":"Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65:704\u20139.","journal-title":"Eur Urol"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2221-5","volume":"16","author":"F Meng","year":"2016","unstructured":"Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer. 2016;16:1\u20137.","journal-title":"BMC Cancer"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1002\/cncr.26623","volume":"118","author":"B Ehdaie","year":"2012","unstructured":"Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118:3397\u2013406.","journal-title":"Cancer"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","volume":"61","author":"JC Hu","year":"2012","unstructured":"Hu JC, Williams SB, O\u2019Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61:1119\u201328.","journal-title":"Eur Urol"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.eururo.2015.06.022","volume":"70","author":"AJ Klil-Drori","year":"2016","unstructured":"Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol. 2016;70:56\u201361.","journal-title":"Eur Urol"},{"key":"150_CR13","unstructured":"Noel PH. Using VA corporate data warehouse for health services research. San Antonio, Texas: VA Information Resource Center; 2012. p. 1-58."},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.18865\/ed.26.1.113","volume":"26","author":"PF Coogan","year":"2016","unstructured":"Coogan PF, Castro-Webb N, Yu J, O\u2019Connor GT, Palmer JR, Rosenberg L. Neighborhood and individual socioeconomic status and asthma incidence in African American women. Ethn Dis. 2016;26:113\u201322.","journal-title":"Ethn Dis"},{"key":"150_CR16","volume-title":"Analysis of observational health care data using SAS.","author":"D Faries","year":"2010","unstructured":"Faries D, Leon AC, Haro JM, Obenchain RL. Analysis of observational health care data using SAS. Cary, NC: SAS Institute Inc; 2010."},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy. J Clin Oncol. 2006;24:3979\u201383.","journal-title":"J Clin Oncol"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"150_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","volume":"71","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318\u201322.","journal-title":"Urology"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","volume":"63","author":"MR Smith","year":"2004","unstructured":"Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742\u20135.","journal-title":"Urology"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. NEJM. 2005;352:1685\u201395.","journal-title":"NEJM"},{"key":"150_CR22","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/STROKEAHA.108.540781","volume":"40","author":"P Appelros","year":"2009","unstructured":"Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40:1082\u201390.","journal-title":"Stroke"},{"key":"150_CR23","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-15-0518","volume":"229","author":"CK Huang","year":"2016","unstructured":"Huang CK, Lee SO, Chang E, Pang H, Chang C. Androgen receptor (AR) in cardiovascular diseases. J Endocrinol. 2016;229:R1\u2013R16.","journal-title":"J Endocrinol"},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.eururo.2010.04.017","volume":"58","author":"A Morales","year":"2010","unstructured":"Morales A. Words of wisdom. Re: lower testosterone levels predict incident stroke and transient ischemic attack in older men. Eur Urol. 2010;58:182\u20133.","journal-title":"Eur Urol"},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/01.ATV.16.6.749","volume":"16","author":"LI Jeppesen","year":"1996","unstructured":"Jeppesen LI, Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS, Winther K. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol. 1996;16:749\u201354.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.brainres.2005.02.078","volume":"1043","author":"Y Pan","year":"2015","unstructured":"Pan Y, Zhang H, Acharya AB, Patrick PH, Oliver D, Morley JE. Effect of testosterone on function recovery in a castrate male rat stroke model. Brain Res. 2015;1043:195\u2013204.","journal-title":"Brain Res"},{"key":"150_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep24807","volume":"6","author":"D Zhu","year":"2016","unstructured":"Zhu D, Hadoke PWF, Wu J, Vesey AT, Lerman DA, Dweck MR, et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci Rep. 2016;6:24807.","journal-title":"Sci Rep"},{"key":"150_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/cncr.30506","volume":"123","author":"SB Williams","year":"2017","unstructured":"Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, et al. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: the limitations of cancer registry data. Cancer. 2017;123:1617\u201324.","journal-title":"Cancer"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5489\/cuaj.3936","volume":"11","author":"H Kaur","year":"2017","unstructured":"Kaur H, Siemens DR, Black A, Robb S, Barr S, Graham CH, et al. Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: a prospective, longitudinal study. Can Urol Assoc J. 2017;11:33\u201338.","journal-title":"Can Urol Assoc J"},{"key":"150_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41391-018-0059-4","volume":"21","author":"Z Guo","year":"2018","unstructured":"Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21:451\u201360.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1569-9056(14)60960-X","volume":"13","author":"M Nguyen-Nielsen","year":"2014","unstructured":"Nguyen-Nielsen M, Borre M, Horvath-Puho E, Ehrenstein V, Sorensen HT. Risk of venous thromboembolism among prostate cancer patients treated with androgen deprivation therapy in denmark: a population-based cohort study, 1997-2011. Eur Urol. 2014;13:976.","journal-title":"Eur Urol"},{"key":"150_CR32","first-page":"36","volume":"24","author":"SC Yii","year":"2017","unstructured":"Yii SC, Chung SD, Huang CY. The Association between androgen deprivation therapy and pulmonary embolism: a population-based study. J Urol. 2017;24:36\u20137.","journal-title":"J Urol"},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","volume":"11","author":"M Hemelrijck Van","year":"2010","unstructured":"Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010;11:450\u20138.","journal-title":"Lancet Oncol"},{"key":"150_CR34","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1200\/JCO.2016.68.9216","volume":"34","author":"HR Mittakanti","year":"2016","unstructured":"Mittakanti HR, Thomas IC, Shelton JB, Makarov DV, Skolarus TA, Cooperburg MR, et al. Accuracy of prostate-specific antigen values in prostate cancer registries. J Clin Oncol. 2016;34:3586\u20137.","journal-title":"J Clin Oncol"},{"key":"150_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Caducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl J Med. 2015;373:737\u201346.","journal-title":"New Engl J Med"},{"key":"150_CR36","unstructured":"Department of Veterans Affairs. Medication copayments. \nhttps:\/\/www.va.gov\/healthbenefits\/resources\/publications\/IB10-971_medication_copayment_brochure.pdf\n\n. Accessed 01 Sep 2017."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0150-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:08Z","timestamp":1684618448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-019-0150-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1038\/s41391-019-0150-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}